Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
Previous studies have confirmed that limb pain caused by oxaliplatin chemotherapy is related
to spinal cord central sensitization - induced hyperalgesia through oxaliplatin activating
spinal cord NMDA receptor(N-methyl-D-aspartic acid receptor). The investigators speculate
that this may be the same as the mechanism of severe abdominal pain caused by HAIC(Hepatic
Artery Infusion Chemotherapy) during oxaliplatin infusion. The analgesic effect of Esketamine
is mainly related to its inhibition of NMDA receptor in spinal cord. Therefore, this study
hypothesized that Esketamine can inhibit the sensitization of spinal cord center by
inhibiting NMDA receptor, so as to alleviate severe abdominal pain during HAIC perfusion, and
reduce abdominal pain caused by ischemia and inflammation by TACE(transcatheter arterial
chemoembolization) by improving organ perfusion and anti-inflammatory effect, Therefore, it
is expected that Esketamine can better alleviate acute severe abdominal pain caused by
TACE-HAIC (transcatheter arterial chemoembolization combined with Hepatic Artery Infusion
Chemotherapy )treatment than sufentanil, decrease the dosage of opioids, and reduce the
incidence and degree of chronic abdominal pain after treatment.
Phase:
Phase 4
Details
Lead Sponsor:
The Second Affiliated Hospital of Chongqing Medical University